Department of Pathology, Seoul National University Boramae Hospital, Seoul, Korea.
Pathobiology. 2012;79(1):45-53. doi: 10.1159/000332739. Epub 2012 Jan 12.
Leptin contributes to mucin production in colonic epithelium and regulates carcinogenesis via various signalling pathways. We evaluated the proteins involved in mucin-producing carcinogenesis and putative targets for molecular therapy in appendiceal mucinous neoplasms.
Immunohistochemistry and fluorescence in situ hybridization were performed in 22 cases of appendiceal mucinous adenoma, 20 mucinous neoplasms of uncertain malignant potential and 14 mucinous adenocarcinomas.
Leptin, MUC2, MUC5AC, mTOR and ERK were more frequently immunopositive in mucinous adenocarcinomas compared with mucinous adenomas or mucinous neoplasms of uncertain malignant potential (p < 0.05). STAT3 revealed immunopositivity in 82% of tumours, regardless of tumour category. MUC2 immunopositivity was associated with pseudomyxoma peritonei (p < 0.05). None of the tumours exhibited c-kitimmunoexpression, amplification of Her2 or EGFR, or translocation of ALK. The mTOR-immunopositive group of patients had a lower rate of disease-free survival compared with the mTOR-immunonegative group (p < 0.05).
Leptin may collaborate with MUC2 and MUC5AC in mucin-producing carcinogenesis in an mTOR-, STAT3- and ERK-dependent manner. STAT3 may be activated early during tumorigenesis. MUC2 and mTOR (but not c-kit, Her2, EGFR and ALK) may represent targets for molecular therapy in pseudomyxoma peritonei and appendiceal mucinous adenocarcinoma, respectively.
瘦素通过多种信号通路促进结肠上皮的粘蛋白产生,并调节癌变。我们评估了参与粘蛋白产生性癌变的蛋白质以及阑尾粘液性肿瘤中分子治疗的潜在靶点。
对 22 例阑尾粘液性腺瘤、20 例恶性潜能不确定的粘液性肿瘤和 14 例粘液性腺癌进行了免疫组织化学和荧光原位杂交。
与粘液性腺瘤或恶性潜能不确定的粘液性肿瘤相比,粘液性腺癌中瘦素、MUC2、MUC5AC、mTOR 和 ERK 的免疫阳性率更高(p<0.05)。STAT3 在 82%的肿瘤中呈免疫阳性,而与肿瘤类别无关。MUC2 的免疫阳性与腹膜假粘液瘤相关(p<0.05)。无肿瘤表现出 c-kit 免疫表达、Her2 或 EGFR 扩增或 ALK 易位。mTOR 免疫阳性组的无病生存率低于 mTOR 免疫阴性组(p<0.05)。
瘦素可能通过 mTOR、STAT3 和 ERK 依赖的方式与 MUC2 和 MUC5AC 共同参与粘蛋白产生性癌变。STAT3 可能在肿瘤发生的早期被激活。MUC2 和 mTOR(但不是 c-kit、Her2、EGFR 和 ALK)可能分别代表腹膜假粘液瘤和阑尾粘液性腺癌分子治疗的靶点。